Ambu A/S
Abonner på opdateringer Ambu A/S
Abonner på udvalgte opdateringer Ambu A/S ved at registrere din mailadresse nedenfor. Du kan altid opsige dit abonnement igen.
Anders HjortHead of Investor Relations
Tlf:+45 2892 8881anhj@ambu.comTine Bjørn SchmidtDirector of Corporate Communications
Tlf:+45 2264 0697tisc@ambu.comSince 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 5,000 people in Europe, North America, Latin America and Asia Pacific.
For more information, please visit Ambu.com.
- Ambu A/S
- Baltorpbakken 13
- 2750 Ballerup
- +45 7225 2000
- www.ambu.com
Selskabsmeddelelser
29
MenuREPORTING OF TRANSACTIONS MADE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES10.11.2025 13:21:35 CET | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made by Executive Management. Company announcement no. 5 2025/26.
2 vedhæftninger
REPORTING OF TRANSACTIONS MADE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES7.11.2025 16:12:59 CET | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made by Executive Management. Company announcement no. 4 2025/26.
2 vedhæftninger
NOTICE OF ANNUAL GENERAL MEETING OF AMBU A/S7.11.2025 13:00:00 CET | Ambu A/S | Notice to general meeting
Notice is hereby given of the annual general meeting of Ambu A/S, CVR no. 63 64 49 19, which is held on Wednesday, 3 December 2025 at 3:00 pm (CET) at the company’s address at Baltorpbakken 13, 2750 Ballerup. BOARD OF DIRECTORS The Board of Directors proposes re-election of Jørgen Jensen as Chair of the Board and Shacey Petrovic as Vice Chair. The Board of Directors proposes that David Hale, Simon Hesse Hoffmann, Susanne Larsson, and Michael del Prado are all re-elected. The notice for this year’s annual general meeting, including information about the proposed Board candidates, is enclosed. This notice is available in Danish- and English-language versions. In the event of discrepancies, the English version shall prevail. Ambu A/S offers the possibility of viewing the annual general meeting 2025 via live webcast on Ambu’s website. Please refer to the notice for further information. Company announcement no. 3 2025/26.
3 vedhæftninger
ANNUAL REPORT 2024/255.11.2025 07:10:01 CET | Ambu A/S | Annual Financial Report
Today, Ambu releases its annual report for the 2024/25 financial year. For the full year, Ambu reported 13.1% organic revenue growth. This was driven by Endoscopy Solutions growing 15.4% and Anesthesia & Patient Monitoring growing 9.9%. Ambu’s EBIT margin before special items reached 13.0%, and the company’s free cash flow before acquisitions totaled DKK 407m. The financial outlook for the 2025/26 financial year is set as follows: 10-13% organic revenue growth and 12-14% reported EBIT margin before special items. Excluding tariff impacts of ~2%-pts, EBIT margin is expected to be 14-16% given the current schedule of expected tariffs. Mitigation action, including investing in Americas, are ongoing, and the effect will diminish over the coming years. “We have delivered another strong year at Ambu of double-digit organic growth and profitability, successfully concluding our turnaround with our ZOOM IN strategy and setting the stage for what’s next. We now are entering a new era of accelera
5 vedhæftninger
INTERIM REPORT FOR Q4 2024/25 AND OUTLOOK FOR FY 2025/265.11.2025 07:00:07 CET | Ambu A/S | Annual Financial Report
Solid growth in Q4 enables Ambu to close the financial year within the current guidance range, delivering 13.1% organic growth and a 13.0% EBIT margin. This consistent momentum highlights the resilience and strength of Ambu’s business model. Looking toward next year, Ambu expects 10-13% organic growth, driven by increased overall procedure volume and continued single-use conversion, and an EBIT margin of 12-14%, supported by continued operating leverage, though partially offset by short-term tariff costs. Excluding tariff impacts of ~2%-pts, EBIT margin is expected to be 14-16% given the current schedule of expected tariffs. Mitigation actions, including investing in Americas, are ongoing, and the effect will diminish over the coming years. “In line with our guidance, we delivered solid financial results, achieving 10.0% organic growth in Q4 and 13.1% for the full year. This performance was fueled by strong momentum in Endoscopy Solutions across all business areas, alongside extraordin
2 vedhæftninger
AMBU ANNOUNCES ZOOM AHEAD STRATEGY WITH INCREASED LONG-TERM FINANCIAL TARGETS30.9.2025 21:31:58 CEST | Ambu A/S | Inside information
Ambu announces its next-era strategy, ZOOM AHEAD, including a long-term aspiration of achieving global endoscopy leadership. With this strategy, Ambu extends its long-term financial targets through FY 2029/30 and increases its 5-year organic revenue CAGR to 11-13%, up from the previous +10% target set for FY 2027/28. The EBIT margin target for FY 2029/30 is set at +20%, while the EBIT margin target for FY 2027/28 is maintained.
2 vedhæftninger
AMBU FINANCIAL CALENDAR 2025/2630.9.2025 17:12:42 CEST | Ambu A/S | Financial Calendar
This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2025/26, as well as the date of Ambu’s annual general meeting. 2025 5 November 2025: Annual report 2024/25 3 December 2025: Annual general meeting 2025 2026 4 February 2026: Earnings Release Q1 2025/26 6 May 2026: Earnings Release Q2 2025/26 26 August 2026: Earnings Release Q3 2025/26 30 September 2026: End of fiscal year 2025/26 5 November 2026: Annual Report 2025/26 2 December 2026: Annual general meeting 2026 Deadline for the inclusion of specific items on the agenda for the annual general meeting 2025 is 21 October 2025.
2 vedhæftninger
INTERIM REPORT FOR Q3 2024/2522.8.2025 07:00:01 CEST | Ambu A/S | Interim report (Q1 and Q3)
In the third quarter of the 2024/25 financial year, Ambu delivered 12.0% organic revenue growth and an 11.3% EBIT margin before special items. This was driven by continued growth in Endoscopy Solutions, which grew 15.9%, and solid performance in Anesthesia & Patient Monitoring, which grew 6.4%. This brings the organic growth for the first nine months to 14.3% and the EBIT margin to 13.9%. The financial guidance for organic revenue growth for 2024/25 is updated to reflect the continued solid growth and is now expected to be 12-14% (previously 11-14%). “I am pleased with the continued solid growth momentum in our third quarter. With 15.9% growth in Endoscopy Solutions and portfolio expansions in pulmonology and urology, we are deepening our presence in high-growth markets. On the back of solid revenue performance in Endoscopy Solutions and strong growth in Anesthesia & Patient Monitoring, we are raising the lower end of our organic revenue guidance to 12-14% for the full year. We maintai
2 vedhæftninger
Reporting of transactions made by persons discharging managerial responsibilities16.5.2025 09:55:35 CEST | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Company announcement no. 15
2 vedhæftninger
Reporting of transactions made by persons discharging managerial responsibilities13.5.2025 11:37:01 CEST | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.
2 vedhæftninger
INTERIM REPORT FOR Q2 2024/25 AND THE HALF-YEAR7.5.2025 07:00:01 CEST | Ambu A/S | Half Year financial report
In the second quarter of the 2024/25 financial year, Ambu delivered 11.7% organic revenue growth and a 14.4% EBIT margin before special items. This was driven by continued growth in Endoscopy Solutions, which grew by 13.1%, and strong performance in Anaesthesia & Patient Monitoring, which grew by 9.8%. This brings the organic growth for the half-year to 15.4% and the EBIT margin to 15.2%. The financial guidance for 2024/25 is maintained. “I am proud that Ambu continues to deliver solid growth and profitability, while advancing our innovation for strong future growth. During the quarter, we initiated the launch of our video laryngoscopy solution, fully integrated with our pulmonology portfolio, and further strengthened our urology portfolio with the continued introduction of our ureteroscopy solution. While it is still too early to anticipate large revenue contributions from these new launches, we maintained strong momentum in our Endoscopy Solutions business, achieving 16.7% organic g
2 vedhæftninger
Launch of Long-Term Incentive Plan for Executive Management and key employees31.1.2025 09:35:34 CET | Ambu A/S | Other information disclosed according to the rules of the Exchange
Ambu A/S (Ambu) launches a new share based Long-Term Incentive Plan (LTIP) for the Executive Management and selected key employees for 2024/25, in accordance with Ambu’s Remuneration Policy. The LTIP is designed to align the interests of employees and shareholders, ensuring that employees are retained and rewarded for their dedicated efforts in achieving the company’s strategic and long-term objectives. The LTIP for 2024/25 has been approved by the Board of Directors. The LTIP implies the grant of a total of 175,477 performance share units (PSUs) for 2024/25. These grants will be issued with retroactive effect from 1 January 2025. Of these, 49,246 PSUs are allocated to the Executive Management, while 126,231 of the PSUs are allocated to other key employees. The LTIP is tied to the financial year 2024/25. The performance period covers the full financial year, and the final allocation of PSUs depends on the achievement of key performance indicators (KPIs) relating to organic revenue grow
2 vedhæftninger
INTERIM REPORT FOR Q1 2024/2530.1.2025 07:00:01 CET | Ambu A/S | Interim report (Q1 and Q3)
In the first quarter of the 2024/25 financial year, Ambu delivered 19.5% organic revenue growth and a 16.1% EBIT margin before special items, driven by continued solid momentum in Endoscopy Solutions, which grew by 20.6%, and strong performance in Anaesthesia & Patient Monitoring, which grew by 17.8%, mainly related to price increases and solid volume growth. On 9 January, 2025, Ambu adjusted its full-year financial guidance by upgrading the expectations for organic revenue growth to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%). The upgrade was mainly related to strong performance in Anaesthesia & Patient Monitoring, supported by continued solid growth in Endoscopy Solutions. “I am pleased with the strong start we have had to the financial year, delivering growth and profitability above expectations and achieving notable milestones. We continued our strong momentum in Endoscopy Solutions, with robust pulmonology growth, and delivered
2 vedhæftninger
AMBU RAISES FINANCIAL OUTLOOK FOR 2024/259.1.2025 18:28:39 CET | Ambu A/S | Inside information
Today, Ambu announces preliminary Q1 2024/25 results and raises expectations for the full 2024/25 financial year. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%). The raised organic growth outlook is mainly driven by better-than-expected revenue growth in Anaesthesia & Patient Monitoring, driven by price increases and solid volume growth. In addition, the raised outlook is supported by continued strong organic growth in Endoscopy Solutions, driven by solid pulmonology momentum and continued strong growth across urology, ear-nose-throat (ENT) and gastroenterology (GI). Furthermore, the raised EBIT margin outlook is driven by continued strengthened operational leverage in OPEX from organic revenue growth and is also positively affected by the strengthening of the USD/DKK currency, relative to the previous outlook from 5 November 2024. Finally, the updated EBIT guidance reflects the increase
2 vedhæftninger
DECISIONS OF THE ANNUAL GENERAL MEETING OF AMBU A/S4.12.2024 16:18:26 CET | Ambu A/S | Decisions of general meeting
Today, 4 December 2024, Ambu A/S held its Annual General Meeting, at which the following items were adopted: Approval of the Company’s annual report and consolidated financial statements The presented audited annual report for the financial year 2023/24 was adopted by the shareholders. Approval of the remuneration report The proposed and presented remuneration report for the financial year 2023/24 was adopted by the shareholders. Approval of the appropriation of profit in accordance with the adopted annual report The Ambu Group reported a net profit for the year of DKK 235 million. The Board of Directors proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the Group’s net profit, whereas the remaining part of the net profit be carried forward to next year. Approval of the Board of Directors' remuneration for the financial year 2024/25 The Board of Dir
2 vedhæftninger
Reporting of transactions made by persons discharging managerial responsibilities3.12.2024 15:29:45 CET | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Company announcement no. 8 2024-2025
2 vedhæftninger
Reporting of transactions made by persons discharging managerial responsibilities22.11.2024 16:01:18 CET | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Company announcement no. 7 2024-2025
2 vedhæftninger
Reporting of transactions made by persons dischargingmanagerial responsibilities22.11.2024 16:00:00 CET | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Company announcement no. 6 2024-2025
2 vedhæftninger
NOTICE OF THE ANNUAL GENERAL MEETING 2024 OF AMBU A/S8.11.2024 12:15:29 CET | Ambu A/S | Notice to general meeting
Notice is hereby given of the annual general meeting of Ambu A/S, CVR no. 63 64 49 19, which is held on Wednesday, 4 December 2024 at 1:00 pm (CET) at the company’s address at Baltorpbakken 13, 2750 Ballerup. Board of Directors The Board of Directors proposes re-election of Jørgen Jensen as Chair of the Board and Shacey Petrovic as Vice Chair. The Board of Directors proposes that Susanne Larsson, Michael del Prado and Simon Hesse Hoffmann are all re-elected. Furthermore, the Board of Directors proposes that David Hale be elected as a new member to the Board of Directors. Christian Sagild has decided not to run for re-election. The notice for this year’s annual general meeting, including information about the proposed Board candidates, is enclosed. This notice is available in Danish and English-language versions. In the event of discrepancies, the English version shall prevail. Ambu A/S offers the possibility of viewing the annual general meeting 2024 via live webcast on Ambu’s website.
3 vedhæftninger
Reporting of transactions made by persons discharging managerial responsibilities7.11.2024 16:44:22 CET | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares.
2 vedhæftninger
- 1
- 2
- Sidste
- >>
Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 5,000 people in Europe, North America, Latin America and Asia Pacific.
For more information, please visit Ambu.com.
- Ambu A/S
- Baltorpbakken 13
- 2750 Ballerup
- +45 7225 2000
- www.ambu.com